11/25
08:45 am
coya
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences [Yahoo! Finance]
Low
Report
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences [Yahoo! Finance]
11/25
08:00 am
coya
ReAlta Life Sciences Appoints Dr. Howard Berman as Executive Chairman
Low
Report
ReAlta Life Sciences Appoints Dr. Howard Berman as Executive Chairman
11/25
08:00 am
coya
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences
Low
Report
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences
11/24
07:02 am
coya
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/15
01:42 am
coya
Coya Therapeutics (NASDAQ:COYA) was upgraded by analysts at
Wall Street
Medium
Report
Coya Therapeutics (NASDAQ:COYA) was upgraded by analysts at
Wall Street
11/14
08:26 am
coya
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.
Low
Report
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.
11/13
01:39 pm
coya
Coya Therapeutics (NASDAQ:COYA) had its price target raised by analysts at BTIG Research from $15.00 to $16.00. They now have a "buy" rating on the stock.
Low
Report
Coya Therapeutics (NASDAQ:COYA) had its price target raised by analysts at BTIG Research from $15.00 to $16.00. They now have a "buy" rating on the stock.
11/12
02:21 pm
coya
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
Low
Report
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
11/12
08:00 am
coya
Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
Low
Report
Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
11/5
11:02 am
coya
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at Lake Street Capital.
Low
Report
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at Lake Street Capital.
11/4
08:00 am
coya
Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo
Medium
Report
Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo
10/27
04:01 pm
coya
Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
Low
Report
Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
10/24
08:10 pm
coya
Coya Therapeutics (COYA) Valuation in Focus After Follow-On Equity Offering Announced [Yahoo! Finance]
Low
Report
Coya Therapeutics (COYA) Valuation in Focus After Follow-On Equity Offering Announced [Yahoo! Finance]
10/24
06:30 am
coya
Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock
Medium
Report
Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock
10/23
04:31 pm
coya
Coya Therapeutics Announces Proposed Public Offering of Common Stock
Medium
Report
Coya Therapeutics Announces Proposed Public Offering of Common Stock
10/8
02:23 pm
coya
Phantom Neuro CEO Connor Glass to Present during BioFuture™ 2025 [Yahoo! Finance]
Low
Report
Phantom Neuro CEO Connor Glass to Present during BioFuture™ 2025 [Yahoo! Finance]
10/7
08:22 am
coya
Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function [Yahoo! Finance]
Medium
Report
Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function [Yahoo! Finance]
10/7
08:00 am
coya
Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function
Medium
Report
Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function
9/30
08:05 am
coya
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $15.00 price target on the stock.
Low
Report
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $15.00 price target on the stock.
9/29
09:50 am
coya
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $18.00 price target on the stock.
Low
Report
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $18.00 price target on the stock.
9/29
08:21 am
coya
Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia [Yahoo! Finance]
Low
Report
Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia [Yahoo! Finance]
9/29
08:00 am
coya
Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia
Low
Report
Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia
9/22
08:15 am
coya
Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis [Yahoo! Finance]
Low
Report
Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis [Yahoo! Finance]
9/22
08:00 am
coya
Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis
Low
Report
Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis
9/17
08:05 am
coya
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.
Medium
Report
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.